{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Tb-500",
    "short_name": "TB-500",
    "aliases": [
      "Thymosin Beta-4 fragment",
      "TB500"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Unapproved peptide commonly discussed in recovery contexts. Often conflated with Thymosin Beta-4 (TÎ²4) biology; products vary and claims frequently exceed evidence."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-17",
      "human_use_note": "TB-500 is not an approved therapeutic drug. Evidence for many recovery claims is primarily preclinical; human evidence for TB-500 specifically is limited."
    },
    "structure": {
      "sequence_oneletter": "",
      "amino_acid_seq": "",
      "molecular_formula": "",
      "molecular_weight": null,
      "structure_image_url": ""
    },
    "risk": {
      "current_score": 6,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "animal",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Key uncertainty is that many benefits are inferred from broader thymosin beta-4 biology and animal work, while real-world risk includes sourcing purity and unregulated administration. Developmental risk flagged due to common youth-athlete interest and limited safety characterization."
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "low",
          "evidence_grade": "animal",
          "text": "TB-500 is a peptide product marketed in recovery contexts, often linked to thymosin beta-4 biology. Many claims rely on preclinical data; human outcome evidence for TB-500 as sold is limited.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "varies",
          "unit": "study-dependent",
          "min": null,
          "max": null,
          "frequency": "varies",
          "duration": "varies",
          "population_group": "general",
          "notes": "Descriptive only. This app does not provide protocols. Not instructions.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "developmental_risk_block": [
        {
          "title": "Developmental / Adolescent risk",
          "population_group": "adolescent",
          "confidence": "low",
          "evidence_grade": "mechanistic_only",
          "text": "Because TB-500 claims are often preclinical and safety is not well characterized, adolescents should treat uncertainty as meaningful risk, especially given real-world sourcing variability.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "interaction_summary": []
    },
    "interactions": {
      "drug_classes": [],
      "supplement_classes": [],
      "peptides": []
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Thymosin beta-4 biology and tissue repair (review; context for claims)",
        "source_type": "pmc",
        "source_id": "PMC4007404",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4007404/",
        "published_date": "2014-01-01",
        "evidence_grade": "animal",
        "notes": "Broad review of thymosin beta-4 biology; supports mechanistic plausibility in animals but does not establish TB-500 outcomes in humans.",
        "year": 2014
      }
    ],
    "changelog": [
      {
        "date": "2026-01-17",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for TB-500",
        "detail": "Added recovery-context peptide entry with strong preclinical framing; flagged developmental risk and sourcing uncertainty.",
        "evidence_refs": [
          "E1"
        ]
      }
    ],
    "meta": {
      "appears_in_blends": [
        "bpc-157-tb-500",
        "glow",
        "klow"
      ]
    },
    "topics": {
      "primary": [
        "topic_injury_healing",
        "topic_muscle_recovery"
      ]
    },
    "slug": "tb-500"
  },
  "canonical_name": "Tb-500"
}
